Patent ID: 8535714

Claim:
A tablet comprising: about 5 to about 200 μg sufentanil or pharmaceutically acceptable salts thereof (expressed as the free base of sufentanil), 60-95 wt % of one or more bulking agents, 1-5 wt % of one or more hydrogel forming excipients, and 1-10 wt % of one or more lubricants, wherein: said tablet has a volume less than about 30 μL, and when said tablet is adhered to the oral mucosa of a patient during the period of drug delivery: a) at least 55% of the total amount of sufentanil in the tablet is delivered via the oral transmucosal route; b) at least 90% of the total amount of sufentanil delivered to the patient, as measured by plasma concentration, is delivered via the oral transmucosal route; c) said tablet provides a mean T max of about 15 minutes to about 80 minutes; d) said tablet provides a mean T max with a coefficient of variation of less than 40%; and e) said tablet provides a dose-normalized mean C max of about 1.59-2.75 pg/mL per meg dosed.